Cochrane for Clinicians
Putting Evidence into Practice
Immediate-Release Methylphenidate for the Treatment of ADHD in Adults
Am Fam Physician. 2015 Apr 1;91(7):445-446.
Should we prescribe immediate-release methylphenidate (Ritalin) to adults with attention-deficit/hyperactivity disorder (ADHD)?
In adults with ADHD, immediate-release methylphenidate improves symptoms of hyperactivity, impulsiveness, and inattentiveness compared with placebo. Short-term adverse effects such as weight loss and decreased appetite do not appear to be serious. However, larger studies of longer duration are needed to evaluate for cardiovascular outcomes. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
ADHD is a common diagnosis in primary care, with an estimated prevalence of 4.4% in the adult population.1 An estimated 35% of children with ADHD still meet criteria for ADHD as adults.2 Many more children will no longer meet criteria for ADHD as adults, but will continue to manifest some of the core symptoms (i.e., hyperactivity, inattentiveness, or impulsiveness). Compared with control patients, adults with ADHD are more likely to have other psychiatric comorbidities (e.g., anxiety, bipolar disorder, substance abuse), interpersonal impairments, and difficulty with employment.2
This Cochrane review included 11 randomized, double-blind, placebo-controlled trials examining the effectiveness of immediate-release methylphenidate in 474 participants. Compared with placebo, methylphenidate decreased symptoms of hyperactivity with a standardized mean difference (SMD) of −0.60 (95% confidence interval [CI], −1.11 to −0.09); inattentiveness with an SMD of −0.66 (95% CI, −1.02 to −0.30); and impulsiveness with an SMD of −0.62 (95% CI, −1.08 to −0.17). Looking at the overall change in condition, the pooled studies demonstrated an SMD of −0.72 (95% CI, −1.12 to −0.32), favoring methylphenidate over placebo.
The effects of treatment with methylphenidate on anxiety and depression symptoms were equivocal; some studies showed benefit, whereas others demonstrated no effect. Subgroup analysis showed high-dose methylphenidate (more than 0.9 mg per kg per day) to be no more effective than low-dose methylphenidate (0.9 mg per kg per day or less) in treating hyperactivity, impulsiveness, or inattentiveness.
The main adverse effects of methylphenidate use in children also pertain to adults. Decreased appetite was reported in six studies, and significant weight loss was reported in three studies. Insomnia, jitteriness, sweating, and tremor also occurred. There were reports of significantly elevated blood pressure and heart rate in some of the studies, but none revealed an increased risk of cardiovascular events or death. The number of patients studied is too small and the length of the trials is too short to detect a clinically important increase in cardiovascular events, if one exists.
This Cochrane review concluded that, compared with placebo, immediate-release methylphenidate is an effective treatment for adults with ADHD, but the review had some limitations. The study participants were limited to individuals from the United States, Canada, and the Netherlands without significant comorbid psychiatric issues, so caution must be used when generalizing the results to other populations. Because the trials span approximately 35 years, there is some variation in the assessment tools used and the diagnosis rates. The size (the largest included 146 participants) and duration (the longest was 17 weeks) of the trials impose serious limitations for detecting long-term adverse effects and the effectiveness of methylphenidate over time. Despite these limitations, the included trials provide evidence in support of current recommendations that methylphenidate be considered first-line therapy in the management of adult ADHD.3
SOURCE: Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2014;9:CD005041.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD005041.
1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723.
2. Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.
3. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179–203.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2015 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Jul 1, 2020
Access the latest issue of American Family Physician